NEW YORK – GlaxoSmithKline yesterday announced that new data from its ongoing Phase I/II GARNET study evaluating the anti-PD-1 monoclonal antibody dostarlimab showed the drug provided clinically meaningful results among women with recurrent or advanced mismatch repair-deficient (dMMR) endometrial cancer who had disease progression during or after a platinum-based treatment regimen.
The data were accepted as a late-breaking abstract and presented as part of the Society of Gynecologic Oncology's 2020 virtual congress.